Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 693 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and... February 4, 2026 Simple Hysterectomy May Expand Treatment Options for Early-Stage Cervical Cancer March 27, 2024 Risk of Distant Recurrence of ER-Positive Breast Cancer in Premenopausal Women... May 8, 2021 Mental Health Awareness for Health Care Providers May 21, 2021 Load more HOT NEWS ‘Family Haven’ Gives Homeless Parents & Their Kids Hope And A... How targeted screening can help the NHS save lives from lung... FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer ESMO Asia Congress 2022, 2-4 December 2022
